BioCentury | Jul 14, 2014
Clinical News

Clopidogrel/acetylsalicylic acid regulatory update

...EMA’s CHMP recommended approval of clopidogrel/acetylsalicylic acid from Teva to prevent atherothrombotic events in adult patients already...
...as a generic in Europe. Teva Pharmaceutical Industries Ltd . (NYSE:TEVA), Petah Tikva, Israel Product: Clopidogrel/acetylsalicylic acid...
BioCentury | Nov 21, 2013
Targets & Mechanisms

Riding the integrin wave in thrombosis

The use of platelet integrin a 2b b 3 inhibitors in thrombosis, while clinically very effective, is associated with a high risk of bleeding that has limited their use. Now, researchers at the University of...
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

...NASDAQ:BMRN) Amifampridine Lambert Eaton Myasthenic Syndrome (LEMS) EU Bristol-Myers Squibb Co. (NYSE:BMY)/sanofi-aventis Group (Euronext:SAN; NYSE:SNY) DuoPlavin/DuoCover...
BioCentury | Apr 5, 2010
Finance

1Q Approvals/1Q Setbacks

...approves DuoPlavin/DuoCover to prevent atherothrombotic events in patients already taking Plavix clopidogrel and acetylsalicylic acid. DuoPlavin/DuoCover...
BioCentury | Mar 29, 2010
Clinical News

DuoPlavin/ DuoCover clopidogrel/acetylsalicylic acid regulatory update

...The European Commission approved an MAA from Bristol-Myers for DuoPlavin/DuoCover to prevent atherothrombotic events in adults...
...Co. (NYSE:BMY), New York, N.Y. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: DuoPlavin / DuoCover clopidogrel/acetylsalicylic acid...
BioCentury | Mar 25, 2010
Company News

EC approves DuoPlavin/DuoCover

...an MAA from Bristol-Myers Squibb Co. (NYSE:BMY) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY) for DuoPlavin / DuoCover...
.../ DuoCover to prevent atherothrombotic events in patients already taking Plavix clopidogrel and acetylsalicylic acid. DuoPlavin/DuoCover...
BioCentury | Jan 4, 2010
Clinical News

DuoPlavin/DuoCover clopidogrel/acetylsalicylic acid regulatory update

...EMEA's CHMP issued a positive opinion on an MAA from Bristol-Myers for DuoPlavin/DuoCover, a fixed-dose combination...
...Co. (NYSE:BMY), New York, N.Y. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: DuoPlavin / DuoCover clopidogrel/acetylsalicylic acid...
BioCentury | Jan 12, 2009
Finance

2009 milestones

...Pharmacon (OSE:BIOTEC) Soluble beta-1,3/1,6-glucan Diabetic ulcers Ph III data 2H09 Bristol-Myers (NYSE:BMY)/ sanofi-aventis (Euronext:SAN; NYSE:SNY) DuoPlavin...
BioCentury | Jul 7, 2008
Finance

2Q approvals

...study groups in the U.S. trial Bristol-Myers (NYSE:BMY)/ The partners withdraw an MAA for DuoPlavin clopidogrel/acetylsalicylic acid...
BioCentury | Jun 2, 2008
Clinical News

DuoPlavin clopidogrel/acetylsalicylic acid regulatory update

...EMEA said Bristol-Myers and sanofi-aventis withdrew an MAA for DuoPlavin clopidogrel/acetylsalicylic acid to prevent atherothrombotic events in...
...Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Product: DuoPlavin clopidogrel/acetylsalicylic acid...
Items per page:
1 - 10 of 11